Inflectra and Infusion site induration - a phase IV clinical study of FDA data

Summary:

Infusion site induration is reported as a side effect among people who take Inflectra (infliximab-dyyb), especially for people who are have been taking the drug for 6 - 12 months also take Prednisone, and have Ulcerative colitis.

The phase IV clinical study analyzes which people have Infusion site induration when taking Inflectra. It is created by eHealthMe based on reports of 52,342 people who have side effects when taking Inflectra from the FDA, and is updated regularly.

What is Inflectra?

Inflectra has active ingredients of infliximab-dyyb. eHealthMe is studying from 52,370 Inflectra users. Check the latest studies of Inflectra.

What is Infusion site induration?

Infusion site induration is found to be associated with 155 drugs and 119 conditions by eHealthMe. Check the latest studies of Infusion site induration.



On Jul, 07, 2026

52,342 people reported to have side effects when taking Inflectra.
Among them, 25 people (0.05%) have Infusion site induration.

Could Inflectra cause Infusion site induration?

Among these 25 people:

How long have people been on Inflectra when they have Infusion site induration? *

  • < 1 month: 30 %
  • 1 - 6 months: 20 %
  • 6 - 12 months: 40 %
  • 1 - 2 years: 10 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

What are other drugs people take besides Inflectra? *

  1. Prednisone: 16 people, 64.00%
  2. Methotrexate: 10 people, 40.00%
  3. Gravol: 8 people, 32.00%
  4. Acetaminophen: 7 people, 28.00%
  5. Hydrocortisone: 7 people, 28.00%
  6. Dimenhydrinate: 6 people, 24.00%
  7. Calcium: 3 people, 12.00%
  8. Benadryl: 2 people, 8.00%
  9. Tylenol: 2 people, 8.00%
  10. Aspirin: 1 person, 4.00%

What are other side effects people have besides Infusion site induration? *

  1. Weight Decreased: 12 people, 48.00%
  2. Infusion Site Extravasation (flow of (blood or lymph) from infusion site): 10 people, 40.00%
  3. Itching: 10 people, 40.00%
  4. Infusion Site Erythema (reddening of the skin at infusion site): 9 people, 36.00%
  5. Weight Increased: 9 people, 36.00%
  6. Pain: 9 people, 36.00%
  7. Blood Pressure Systolic Increased: 9 people, 36.00%
  8. Heart Rate Decreased: 9 people, 36.00%
  9. Foot Deformity (functional disability of foot): 8 people, 32.00%
  10. Rheumatoid Nodule (a local swelling or tissue lump with rheumatoid disease): 8 people, 32.00%

What are the existing conditions these people have? *

  1. Ulcerative Colitis (inflammatory bowel disease (ibd). it causes swelling, ulcerations, and loss of function of the large intestine): 9 people, 36.00%
  2. Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 8 people, 32.00%
  3. Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 7 people, 28.00%
  4. Eosinophil Count Abnormal: 1 person, 4.00%
  5. Colitis Microscopic (inflammation of colon with diarrhoea and abdominal cramps): 1 person, 4.00%
  6. Behcet's Syndrome (involves inflammation of the blood vessels): 1 person, 4.00%
  7. Abscess (pus): 1 person, 4.00%

* Approximation only. Some reports may have incomplete information.

Do you take Inflectra and have Infusion site induration?

- Check whether Infusion site induration is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, long term effects of, and alternative drugs to Inflectra:

Infusion site induration treatments and more:

How severe was Infusion site induration and when was it recovered:

Expand to all the drugs that have ingredients of infliximab-dyyb:

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Inflectra:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Infusion site induration:

Browse all the conditions that are associated with Infusion site induration:


How the study uses the data?

The study uses data from the FDA. It is based on infliximab-dyyb (the active ingredients of Inflectra) and Inflectra (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: